Cell-autonomous and non-cell-autonomous mechanisms of HGF/MET-driven resistance to targeted therapies: from basic research to a clinical perspective.
about
Advances in targeted and immunobased therapies for colorectal cancer in the genomic eraMesenchymal Stem/Stromal Cells in Stromal Evolution and Cancer ProgressionImproving the efficacy of chemoradiation with targeted agentsNext-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneityThe role of tumor microenvironment in therapeutic resistanceCetuximab-induced MET activation acts as a novel resistance mechanism in colon cancer cells.NF-κB activation-induced anti-apoptosis renders HER2-positive cells drug resistant and accelerates tumor growth.The c-Met Inhibitor MSC2156119J Effectively Inhibits Tumor Growth in Liver Cancer ModelsMet receptor-induced Grb2 or Shc signals both promote transformation of intestinal epithelial cells, albeit they are required for distinct oncogenic functions.New horizons in tumor microenvironment biology: challenges and opportunitiesIdentification of a novel MET mutation in high-grade glioma resulting in an auto-active intracellular proteinH19 non coding RNA-derived miR-675 enhances tumorigenesis and metastasis of breast cancer cells by downregulating c-Cbl and Cbl-b.Isothiocyanatostilbenes as novel c-Met inhibitors.SFRP2 augments WNT16B signaling to promote therapeutic resistance in the damaged tumor microenvironmentEverolimus induces Met inactivation by disrupting the FKBP12/Met complexMET/HGF pathway activation as a paradigm of resistance to targeted therapies.Three-dimensional bio-printing: A new frontier in oncology research.Cabozantinib for the treatment of kidney cancer.Hypoxia-Driven Mechanism of Vemurafenib Resistance in MelanomaPreclinical and clinical evaluation of MET functions in cancer cells and in the tumor stroma.Impact of bevacizumab in combination with erlotinib on EGFR-mutated non-small cell lung cancer xenograft models with T790M mutation or MET amplification.Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges.Hepatocyte growth factor protects human mesangial cells against apoptosis induced by lead damage.Increase of MET gene copy number confers resistance to a monovalent MET antibody and establishes drug dependence.Enhancer-targeted genome editing selectively blocks innate resistance to oncokinase inhibition.Peritumoral stromal neutrophils are essential for c-Met-elicited metastasis in human hepatocellular carcinoma.Epithelial-to-Pericyte Transition in Cancer.Dual inhibition of MET and SRC kinase activity as a combined targeting strategy for colon cancer.Characterization and structural determination of a new anti-MET function-blocking antibody with binding epitope distinct from the ligand binding domain.Mitochondrial-Targeting MET Kinase Inhibitor Kills Erlotinib-Resistant Lung Cancer Cells.
P2860
Q26751344-6A71BC8E-7D18-4373-BB82-BA4FA01933F5Q26770002-6E9F47C6-0986-455D-9042-AD739E21B6E9Q26850193-A7DD7CC1-CC33-496D-A36F-DF4C2B08B769Q26992272-87FDEE47-CC2B-447D-94F7-EBEBF34CEBF4Q28069049-6194D0FA-010E-4FF0-BBD3-740EB1C1CEE2Q33580500-05BF60B6-CDB9-46F4-92A8-662AD9FA352EQ33632205-64A38A59-BE1C-49C8-9BAB-F270F7919F30Q34309954-EA143CDB-D258-48C4-85D1-D35619D85EB6Q35141465-1614623C-5B91-4050-9B86-9CBF5DE2169CQ35151324-6971A272-384E-4F0E-82A1-AE39F732942BQ35747784-1F797BB9-89C9-42FB-B74B-45816EDC5C94Q36557258-BFE85E73-D7C4-4241-B790-814D7B9874A0Q36562316-A12FF3C2-9C3B-416C-A746-D4C299A817D1Q37195520-85C60E17-0B25-49DD-8571-B61D1E35ED2EQ37457794-2BDCCA64-166B-446A-A836-CFB8E4D416F2Q37597850-D696B9EE-D03F-4DBE-A25A-147691AED729Q37642457-2A05EED4-9675-4AFD-883E-38C97F15C1F9Q38668871-2AC207DE-2BD0-40C3-B7A9-4C7CE09307E1Q38755819-E405EC49-1377-4181-832C-5EF6D6A9525BQ38782345-5B5F84A3-7B00-4B04-AEA7-783A833DF593Q38835312-2F0F463D-ED01-4134-A8EF-DACB04DDD837Q38856729-D8ECF18F-A110-488C-8C2A-730DF0755567Q38963112-64BACACE-37C8-4CDF-81B0-DAA1E6C87FCFQ38976616-5B75D44B-C30A-4AD1-9FC2-81898AB3DDB8Q39032842-149B5AA9-5228-46AD-9CD2-AFB0BEFA2F05Q39181838-5DF88F7D-F4CC-4B2C-8F33-3B79657B007DQ39414887-41403B6D-B014-49C3-A826-B565A0C5F45DQ41116584-98ADAE75-F1EE-42F1-850A-11011EA34D4FQ41490164-CA2027C0-D3E9-4233-AE87-6C2646E01CDFQ41992710-8FA451A8-65D0-4F2C-B1A1-31F11F6E9FB1
P2860
Cell-autonomous and non-cell-autonomous mechanisms of HGF/MET-driven resistance to targeted therapies: from basic research to a clinical perspective.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Cell-autonomous and non-cell-a ...... rch to a clinical perspective.
@en
type
label
Cell-autonomous and non-cell-a ...... rch to a clinical perspective.
@en
prefLabel
Cell-autonomous and non-cell-a ...... rch to a clinical perspective.
@en
P1433
P1476
Cell-autonomous and non-cell-a ...... rch to a clinical perspective.
@en
P2093
Silvia Giordano
Simona Corso
P304
P356
10.1158/2159-8290.CD-13-0040
P577
2013-07-30T00:00:00Z